Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells 3,331 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.00, for a total transaction of $23,317.00. Following the transaction, the chief executive officer now owns 74,123 shares in the company, valued at approximately $518,861. This trade represents a 4.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Atara Biotherapeutics Price Performance

Shares of ATRA stock opened at $6.80 on Friday. The company has a market capitalization of $39.17 million, a price-to-earnings ratio of -0.26 and a beta of 0.46. Atara Biotherapeutics, Inc. has a one year low of $5.40 and a one year high of $20.81. The company’s fifty day moving average price is $9.97 and its 200-day moving average price is $9.73.

Analysts Set New Price Targets

ATRA has been the topic of several recent research reports. RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Finally, Canaccord Genuity Group decreased their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.75.

Institutional Trading of Atara Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Atara Biotherapeutics during the 4th quarter valued at $48,000. Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics during the 4th quarter valued at $169,000. Citadel Advisors LLC raised its position in shares of Atara Biotherapeutics by 2.6% during the 4th quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock valued at $3,558,000 after purchasing an additional 6,873 shares during the period. Bank of America Corp DE raised its position in shares of Atara Biotherapeutics by 0.8% during the 4th quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock valued at $2,731,000 after purchasing an additional 1,543 shares during the period. Finally, Northern Trust Corp purchased a new position in Atara Biotherapeutics during the fourth quarter valued at $149,000. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.